Macrophage Inflammatory Protein 4, Recombinant, Human (MIP-4, CCL18)

Recombinant Human Macrophage Inflammatory Protein-4 is a single, non-glycosylated, polypeptide chain containing 69 amino acids and having a molecular mass of 7813 Daltons.\n\nSequence:\nThe sequence of the first five N-terminal amino acids was determined and was found to be Ala-Gln-Val-Gly-Thr.\n\nDimers and Aggregates:\n(same/less than) 1% as determined by silver-stained SDS-PAGE gel analysis.\n\nBiological Activity:\nMurine Macrophage Inflammatory Protein-4 is fully biologically active when compared to standard. The Activity is calculated by the ability to chemoattract Human T lymphocytes at 1.0-10.0ng/ml.\n\nEndotoxin:\n(same/less than) 0.1ng/ug (IEU/ug) of Recombinant Human MIP-4.\n\nProtein Content:\nMIP-4 protein quantitation was carried out by two independent methods: \n1. UV spectroscopy at 280nm. \n2. Analysis by RP-HPLC, using a calibrated solution of Recombinant Human MIP-4 as a Reference Standard.\n\nReconstitution:\nReconstitute the lyophilized MIP-4 in sterile 18MO-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.\n\nStorage and Stability:\nLyophilized powder may be stored at 4 degrees C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

M1202-70A

Size

2ug

Form

Supplied as a lyophilized powder. No additives.

Purity

(same/more than) 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.

References

1. Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis and regulation by Fc gamma receptors. Radstake TR, Van Der Voort R, De Waal Malefijt M, Figdor CG, Ann Rheum Dis 2004 Aug 26; 2. PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. Struyf S, Schutyser E, Gijsbers K, Van Damme J, Am J Pathol 2003 Nov;163(5):2065-75 3. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Boot RG, Verhoek M, Hollak CE, van Meurs M, Blood 2004 Jan 1;103(1):33-9 4. Unique regulation of CCL18 production by maturing dendritic cells. Vulcano M, Struyf S, Cassatella M, Penna G, J Immunol 2003 Apr 1;170(7):3843-9 5. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. Schutyser E, Struyf S, Opdenakker G, Van de Putte I, J Biol Chem 2002 Jul 5;277(27):24584-93 6. Selective induction of CCL18/PARC by staphylococcal enterotoxins in mononuclear cells and enhanced levels in septic and rheumatoid arthritis. Schutyser E, Struyf S, Put W, Van Damme J, Eur J Immunol 2001 Dec;31(12):3755-62.